Despite recent advances, most previous studies identifying mutations in ctDNA from lung cancer patients focus on advanced-stage cancers and analyze a limited number of genes18, 19, particularly EGFR and KRAS as these are frequently mutated in lung cancers and have implications in targeted therapies14, 20. The gene discussed is KRAS; the disease is lung cancer.